George Horner Iii

Biography

Currently, Mr. Horner is a biotech executive consultant for several private companies in the United States and Europe. Previous, he was CEO of Prestwick Pharmaceuticals, a CNS company that he directed to obtain FDA approval for Tetrabenazine (TBZ), the first drug ever licensed in the United States to treat Huntington’s Disease patients. Prior to that, Mr. Horner was CEO of Vicuron Pharmaceuticals, an anti-infective company that he grew from a market value of $12.8 million to a company sold to Pfizer for $1.9 billion. Additionally, he has held numerous executive, general management, business development and marketing/sales positions with Abbott Laboratories and E.R. Squibb across 4 continents, worldwide. Mr. Horner is Chairman of the Board of Creabilis Therapeutics of Luxembourg, Chairman of the Board of Omthera Pharmaceuticals of Bedminster, New Jersey, USA, and member of the Durata Therapeutics board of directors. 

Research Interest

Bioinformatics & Systems Biology